These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36394590)

  • 41. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Talimogene laherparepvec: First in class oncolytic virotherapy.
    Conry RM; Westbrook B; McKee S; Norwood TG
    Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
    Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
    Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
    Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner.
    Chen P; Huang Y; Bong R; Ding Y; Song N; Wang X; Song X; Luo Y
    Clin Cancer Res; 2011 Dec; 17(23):7230-9. PubMed ID: 21994414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
    Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
    J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma.
    Nakajima S; Mimura K; Saito K; Thar Min AK; Endo E; Yamada L; Kase K; Yamauchi N; Matsumoto T; Nakano H; Kanke Y; Okayama H; Saito M; Neupane P; Saze Z; Watanabe Y; Hanayama H; Hayase S; Kaneta A; Momma T; Ohki S; Ohira H; Kono K
    Mol Cancer Res; 2021 Jun; 19(6):1085-1095. PubMed ID: 33674443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy.
    Schweer D; McAtee A; Neupane K; Richards C; Ueland F; Kolesar J
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway.
    Wang T; Ge Y; Xiao M; Lopez-Coral A; Li L; Roesch A; Huang C; Alexander P; Vogt T; Xu X; Hwang WT; Lieu M; Belser E; Liu R; Somasundaram R; Herlyn M; Kaufman RE
    J Invest Dermatol; 2014 Apr; 134(4):1108-1118. PubMed ID: 24157461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-associated macrophages in oral premalignant lesions coexpress CD163 and STAT1 in a Th1-dominated microenvironment.
    Mori K; Haraguchi S; Hiori M; Shimada J; Ohmori Y
    BMC Cancer; 2015 Aug; 15():573. PubMed ID: 26242181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel targeted iron oxide nanocarrier for inhibiting M2-type macrophages in the tumor microenvironment.
    Tian K; Feng R; Wang X; Wu X; Li L; Liu W; Wu R
    J Cancer Res Ther; 2022 Sep; 18(5):1409-1416. PubMed ID: 36204890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.
    Guo X; Xue H; Shao Q; Wang J; Guo X; Chen X; Zhang J; Xu S; Li T; Zhang P; Gao X; Qiu W; Liu Q; Li G
    Oncotarget; 2016 Dec; 7(49):80521-80542. PubMed ID: 27602954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Taming of the TAMs.
    Seoane J
    Trends Cell Biol; 2016 Aug; 26(8):562-563. PubMed ID: 27394965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.
    Hourani T; Holden JA; Li W; Lenzo JC; Hadjigol S; O'Brien-Simpson NM
    Front Oncol; 2021; 11():788365. PubMed ID: 34988021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
    Hwang I; Kim JW; Ylaya K; Chung EJ; Kitano H; Perry C; Hanaoka J; Fukuoka J; Chung JY; Hewitt SM
    J Transl Med; 2020 Nov; 18(1):443. PubMed ID: 33228719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.